Research programme: cardio-protective therapeutics - CapellaBio/Stem cell Theranostics

Drug Profile

Research programme: cardio-protective therapeutics - CapellaBio/Stem cell Theranostics

Alternative Names: chemoprotectants - CapellaBio/Stem Cell Theranostics

Latest Information Update: 11 Apr 2016

Price : $50

At a glance

  • Originator CapellaBio; Stem Cell Theranostics
  • Class Cardiotonics
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Acute heart failure

Most Recent Events

  • 16 Dec 2015 Early research in Acute heart failure (Prevention) in USA (unspecified route)
  • 16 Dec 2015 Stem Cell Theranostics and CapellaBio agree to co-develop therapeutics in USA for Acute heart failure (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top